Napo pharmaceuticals to exhibit at the october 25-28 annual association of nurses in aids care (anac) conference for mytesi, the company's fda-approved prescription drug

Mytesi® (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with hiv/aids on antiretroviral therapy napo to host educational dinner for nurses about hiv-related diarrhea and mytesi during conference san francisco, ca / accesswire / october 18, 2023 / napo pharmaceuticals (napo), a jaguar health, inc. (nasdaq:jagx) family company, today announced that it will exhibit at the annual association of nurses in aids care (anac) conference, which takes place october 25-28, 2023 at the new orleans marriott in new orleans, louisiana. mytesi (crofelemer) is napo's oral plant-based prescription drug that is fda-approved and commercially available for the symptomatic relief of noninfectious diarrhea in adult patients with hiv/aids on antiretroviral therapy.
JAGX Ratings Summary
JAGX Quant Ranking